- $7.12m
- -$9.18m
- $7.30m
- 37
- 70
- 58
- 55
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.38 | ||
| Price to Tang. Book | 0.38 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.62 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -34.53% | ||
| Return on Equity | -38.45% | ||
| Operating Margin | -80.52% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 7.91 | 12.63 | 5.17 | 6.07 | 7.3 | 6.93 | 7 | 116.62% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Pulmatrix, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat respiratory and other diseases with important unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders, such as acute migraine and serious lung diseases, such as chronic obstructive pulmonary disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). The Company’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes. The Company’s therapeutic candidates include PUR3100, PUR1800, and PUR1900. PUR3100 is the iSPERSE formulation of dihydroergotamine (DHE), for the treatment of acute migraine.
Directors
- Michael Higgins NEC (58)
- Teofilo Raad PRE (51)
- Michelle Siegert VFN (60)
- Anand Varadan DRC (54)
- Richard Batycky IND (53)
- Todd Bazemore IND (51)
- Christopher Cabell IND (52)
- Last Annual
- December 31st, 2023
- Last Interim
- March 31st, 2024
- Incorporated
- September 25th, 2013
- Public Since
- March 21st, 2014
- No. of Shareholders
- 43
- No. of Employees
- 22
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 3,652,285
- Address
- 36 Crosby Drive, Suite 100, BEDFORD, 01730
- Web
- https://www.pulmatrix.com/
- Phone
- +1 7813572333
- Contact
- Timothy McCarthy
- Auditors
- Marcum LLP
Upcoming Events for PULM
Q2 2024 Pulmatrix Inc Earnings Release
Q3 2024 Pulmatrix Inc Earnings Release
Similar to PULM
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Pulmatrix share price?
As of Today at 22:48 UTC, shares in Pulmatrix are trading at $1.98. This share price information is delayed by 15 minutes.
How has the Pulmatrix share price performed this year?
Shares in Pulmatrix last closed at $1.98 and the price had moved by -27.34% over the past 365 days. In terms of relative price strength the Pulmatrix share price has underperformed the S&P500 Index by -42.18% over the past year.
What are the analyst and broker recommendations for Pulmatrix?
The overall consensus recommendation for Pulmatrix is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Pulmatrix dividend yield?
Pulmatrix does not currently pay a dividend.
Does Pulmatrix pay a dividend?
Pulmatrix does not currently pay a dividend.
When does Pulmatrix next pay dividends?
Pulmatrix does not currently pay a dividend.
How do I buy Pulmatrix shares?
To buy shares in Pulmatrix you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Pulmatrix?
As of the previous close price of $1.98, shares in Pulmatrix had a market capitalisation of $7.23m.
Where are Pulmatrix shares listed?
Here are the trading details for Pulmatrix:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: PULM
What kind of share is Pulmatrix?
Based on an overall assessment of its quality, value and momentum Pulmatrix is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Pulmatrix share price forecast for 2024?
The analyst consensus target price for shares in Pulmatrix is $10.00. That is 405.05% above the last closing price of $1.98.
Analysts covering Pulmatrix currently have a consensus Earnings Per Share (EPS) forecast of -$4.50 for the next financial year.
What is the trend in the Pulmatrix share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Pulmatrix. Over the past six months, its share price has underperformed the S&P500 Index by -13.28%.
As of the last closing price of $1.98, shares in Pulmatrix were trading +3.14% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Pulmatrix PE Ratio?
The Pulmatrix PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.98.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Pulmatrix?
Pulmatrix's management team is headed by:
- Michael Higgins - NEC
- Teofilo Raad - PRE
- Michelle Siegert - VFN
- Anand Varadan - DRC
- Richard Batycky - IND
- Todd Bazemore - IND
- Christopher Cabell - IND